⚠️ Community information, not medical advice. 7-OH is sold as a loosely regulated supplement — “7-OH tablets”, “gas station pills”, “7” — and what’s on the label is often not what’s in the product. Anything below is a pharmacology and recovery reference, not dosing guidance and not safety guidance for current use. If you’re trying to come off, the #suboxone-info and #sos-resources pages are where you actually go.
7-OH is the compound this site is named after — and the compound most people here are trying to get off of. It is an opioid. Whatever the gas-station marketing says, whatever the “all-natural kratom alkaloid” framing implies, the practical reality is that 7-OH binds the mu-opioid receptor, produces opioid-class dependence, and goes through opioid-class withdrawal when you stop.
The good news, if there is good news: 7-OH’s pharmacology is actually favorable for coming off it. Short half-life, mu-dominant, fast clearance — the same things that make it easy to get hooked also make it tapereable in days rather than weeks once you commit to stopping.
What it is
7-hydroxymitragynine is one of the natural alkaloids of the kratom plant (Mitragyna speciosa), where it appears in trace amounts — typically well under 1% of total leaf alkaloid content. Mitragynine, the main alkaloid, dominates leaf at 40-66%. So 7-OH-as-it-exists-in-leaf is a minor character.
What’s sold as “7-OH” in tablet, shot, and liquid form is concentrated or semi-synthetic 7-hydroxymitragynine — extracted, isolated, or synthesized to deliver doses far above anything achievable from leaf. A single 5–15 mg 7-OH tablet contains more 7-OH than several grams of leaf would. The marketing language (“kratom enhanced”, “all-natural”) obscures this scale difference; the dependence reality doesn’t.
Pharmacology, briefly
- Mu-opioid receptor: 7-OH binds the µ-receptor 13 to 22 times more strongly than morphine, with Ki around 13–17 nM at the human µ-receptor. Mitragynine, by comparison, has Ki around 160–230 nM — about a 10× difference in binding affinity.
- Agonist character: partial agonist at the µ-receptor with meaningful intrinsic activity (Emax notably higher than mitragynine’s ~34%). Functionally, it produces opioid-class analgesia, sedation, euphoria, and (over time) dependence.
- Receptor selectivity: mu-dominant. Little meaningful activity at κ or δ receptors at typical doses, and far less of the serotonergic and adrenergic activity that leaf carries via its other minor alkaloids (see #minor-alkaloids).
Plasma half-life
Roughly 100 minutes (about 1 hour 40 minutes). This is short by opioid standards — close to immediate-release oxycodone, much shorter than MGM-15’s ~15-hour half-life or methadone’s 24+ hours.
The dosing pattern follows from the half-life: most habitual 7-OH users redose every 3–6 hours during waking hours, and many wake up at night needing a dose. That redosing cadence is the most visible behavioral signature of a 7-OH habit.
How it differs from kratom leaf
Calling 7-OH “kratom” is technically true and practically misleading. The differences that actually matter:
| Property | Leaf kratom (mitragynine-dominant) | Concentrated 7-OH |
|---|---|---|
| Main active alkaloid | Mitragynine (~40-66% of leaf) | 7-OH (isolated) |
| µ-receptor binding affinity | Modest (Ki ~160-230 nM) | High (Ki ~13-17 nM) |
| µ-agonism efficacy | Low (Emax ~34%) | Substantially higher |
| Serotonergic / adrenergic activity | Significant (via minor alkaloids) | Minimal |
| Typical use cadence | Every 4-6 h, often less | Every 3-6 h, often more |
| Dependence trajectory | Slow | Fast (weeks to months) |
| Withdrawal severity | Mild to moderate | Moderate to severe |
| Withdrawal duration (acute) | Several days | 5-10 days |
| Bupe-induction profile | Straightforward | Straightforward (12-18 h) |
The shorthand: kratom leaf is to 7-OH roughly what poppy tea is to heroin — same plant family, vastly different concentration and delivery. The pharmacology that makes 7-OH attractive (faster onset, stronger effect, smaller dose to carry around) is the same pharmacology that makes dependence form quickly.
This is also why tapering off concentrated 7-OH using plain leaf is a real, planned protocol used by some people in this community — the leaf delivers vastly lower concentrations of the same family of alkaloids, so stepping down is a meaningful taper rather than a switch.
Withdrawal profile
Acute 7-OH withdrawal follows a recognizable opioid-withdrawal arc, compressed into days because of the short half-life:
| Time since last dose | What’s happening |
|---|---|
| 6-12 hours | First symptoms — anxiety, restlessness, sweating, runny nose, aches |
| 12-24 hours | Symptoms climb — diarrhea, chills, goosebumps, insomnia, cravings |
| 24-72 hours | Peak — body aches, restless legs, no sleep, profound discomfort |
| Days 3-5 | Symptoms start lifting; sleep returns in fragments |
| Week 2 onward | Acute mostly done; welcome to PAWS |
The peak is genuinely awful but time-limited. Most people are through the worst by day 5, into “functional but drained” by day 7, and out of acute by week 2. The post-acute tail (PAWS) is its own chapter and is usually much more manageable than peak acute.
The SNRI-like component
7-OH itself isn’t particularly active at serotonergic or adrenergic receptors — but the concentrated kratom-derived products people actually use are rarely pure 7-OH. Many are stacked with mitragynine, other minor alkaloids, or undisclosed compounds. Those carry serotonergic (5-HT1A, 5-HT2B) and α-adrenergic activity that gives 7-OH withdrawal an SNRI-discontinuation-like overlay: brain zaps, wired-but-exhausted feeling, autonomic instability. See #suboxone-isnt-working for why this overlay makes bupe alone feel insufficient for some people, and see #helper-meds-info for what addresses the non-opioid side.
Why 7-OH is actually tapereable
Counter-intuitively, the same pharmacology that makes 7-OH addictive is what makes coming off it relatively clean:
- Short half-life means the drug leaves your system fast. Once you stop, plasma 7-OH is gone within ~10 hours. Receptor adaptation starts reversing immediately.
- Mu-dominant binding means a mu-opioid medication like Suboxone (buprenorphine) substitutes cleanly. There’s no delta-receptor component left dangling (unlike MGM-15) and no unusually-tight binding that fights bupe induction (unlike pseudo).
- Predictable bupe-induction window — COWS ≥ 12 usually arrives 12-18 hours after last dose, which fits well into a same-day telehealth Suboxone appointment.
- Short receptor adaptation — because dependence on 7-OH typically develops over months (not years), the underlying receptor changes are less entrenched than they are with long-term full-agonist use.
This is why the rapid-taper protocol in #suboxone-rapid-taper works for so many people coming off 7-OH alone, and why this community leans toward short Suboxone tapers rather than indefinite maintenance for this population specifically. See #suboxone-info for the full overview, including the receptor-occupancy reason we start at low Suboxone doses rather than the clinical-default 16-24 mg.
Common forms
7-OH shows up in retail under a few names and formats:
- Tablets / “7s” — typically 5-15 mg per tablet, often marketed as “tianeptine-free” or “kratom enhanced”. The dominant gas-station format.
- Liquid shots — 1-2 oz bottles labeled by mg or by “potency”, often inconsistent between batches.
- “Pseudo” tablets and shots — these are mitragynine pseudoindoxyl (MP), a different compound that binds even tighter than buprenorphine. Sometimes labeled or co-marketed with 7-OH; the pharmacology is different enough that you need to know which you’ve been on.
- Stacked products — combinations of 7-OH, mitragynine, pseudoindoxyl, and sometimes MGM-15 or MIT-A/DHM. The label may say “kratom extract” and tell you nothing about what’s actually in it.
- Raw 7-OH powder — less common in retail; more common in enthusiast communities. Tends to be the most concentrated form.
If you’re not sure what you’ve been on, that’s important to figure out before induction — the long-acting compounds (MGM-15, MIT-A, pseudo) have different timelines and different induction-window requirements. See the half-life table in #suboxone-cows.
Marketing claims to be skeptical of
Retail 7-OH marketing tends toward a recurring set of claims, most of which don’t survive the pharmacology:
- “Non-addictive” — false. The dependence profile is opioid-class. The withdrawal profile is opioid-class. The receptor mechanism is opioid-class.
- “All-natural / just kratom” — technically the molecule exists in the plant, but the concentrations sold retail are orders of magnitude beyond what leaf delivers. Calling a 15 mg 7-OH tablet “natural” because the alkaloid is plant-derived is the same argument as calling pure morphine “natural” because poppies make it.
- “Safer than opioids” — 7-OH is an opioid. The “safer” claim usually rests on the ceiling-effect-at-the-receptor argument, which has some truth at high doses but doesn’t change the dependence and withdrawal trajectory at typical use levels.
- “Doesn’t cause respiratory depression” — disputed. Pure mitragynine in animal models has shown a respiratory ceiling effect, but real-world products are not pure mitragynine, are often stacked with other alkaloids, and are frequently combined by users with alcohol, benzos, or other depressants — any of which restores respiratory-depression risk. Get Narcan. See #for-loved-ones for more.
- “FDA approved” / “Doctor recommended” — almost always not true. Trace mitragynine appears in some research contexts, but no concentrated 7-OH product has FDA approval as of this writing.
What to do if you’re trying to stop
Three real paths, in increasing order of medical support:
- Cold turkey with helper meds and supplements — works for many people on short-acting 7-OH at moderate doses. #helper-meds-info and #vitamins-supplements.
- Suboxone short taper — the community’s most common path for 7-OH dependence specifically. 5-14 days, structured, low-and-slow induction. #suboxone-info is the overview.
- Plain kratom-leaf taper — a planned, deliberate protocol that uses leaf as a stepdown from concentrated 7-OH. Not for everyone, not for everyone’s dose level, and not a rescue strategy during acute withdrawal. See #tapering-with-leaf.
Whichever path you take, don’t try to navigate it without at least one other person knowing. The Discord and subreddit linked at #community are where most people in this position end up.
Further reading
- Kruegel AC, Grundmann O — Medicinal chemistry and neuropharmacology of kratom — the canonical review.
- Váradi A et al — Mitragynine/corynantheidine pseudoindoxyl as a discovery platform for opioids with reduced side effects — receptor-pharmacology context.
- León F, Obeng S et al — 7-Hydroxymitragynine in Mitragyna speciosa — alkaloid context.
- Wilson LL et al — Optimization of the 7-hydroxymitragynine scaffold — semi-synthetic derivative work.
- Kratom withdrawal timeline (clinical summary).
🩺 Reminder: 7-OH is an opioid. Treat it as one, both in terms of not underestimating dependence development and in terms of using opioid-recovery tools (MAT, helper meds, structured tapers) when coming off. The community here is built around people who have done this; you are not the first person to try.